Isis Pharma earns milestone payment from Biogen

Isis Pharmaceuticals (ISIS) initiates a Phase 1 study for antisense ISIS-DMPKrx, a treatment for Myotonic Dystrophy Type 1 (DM1) and earns a $14M milestone payment from Biogen Idec (BIIB). ISIS-DMPKrx is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells.

From other sites
Comments (1)
  • chicagomary
    , contributor
    Comments (413) | Send Message
    nice news on $ISIS. They have 3 or 4 projects with $BIIB. $BIIB will probably buy $ISIS but I hope not soon;it should be worth much more in a couple years.
    9 Jun 2014, 10:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs